Press Release Test

This is a test

ASCO 2022 | Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development

SUZHOU, China, and ROCKVILLE, MD, May. 27, 2022—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its seven clinical abstracts selected by the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, of which six were selected for presentations and Read More ›

Ascentage Pharma to Present Latest Clinical Data of Lisaftoclax (APG-2575) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas at 2022 European Hematology Association Hybrid Congress

SUZHOU, China, and ROCKVILLE, MD, May. 20, 2022—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it will release the latest results from a Phase I study of lisaftoclax (APG-2575), the company’s novel Bcl-2 selective inhibitor, in Chinese patients with Read More ›

Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib’s Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine

SUZHOU, China, and ROCKVILLE, MD, May. 18, 2022—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a new preclinical study, conducted by the researchers from Fred Hutchinson Cancer Research Center, Seattle, suggests the therapeutic potential of olverembatinib (HQP1351) in inhibiting Read More ›

ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting

SUZHOU, China, and ROCKVILLE, MD, Apr. 27, 2022—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that updated results from seven studies involving the company’s five novel drug candidates will be presented at the 2022 American Society of Clinical Oncology (ASCO) Read More ›

AACR 2022 | Ascentage Presents Six Preclinical Studies

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has presented the latest results from six preclinical studies of the company’s five investigational drug candidates: the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), two key candidates Read More ›

Alrizomadlin(APG-115) Granted RPD by the US FDA in Neuroblastoma

SUZHOU, China, and ROCKVILLE, MD., Mar. 22, 2022 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel MDM2-p53 inhibitor, alrizomadlin (APG-115), was granted a  Rare Pediatric Disease (RPD) designation by the US Food and Drug Administration (FDA), Read More ›

Ascentage Pharma Announces 2021 Annual Results with Commercialization Programs Going Full Steam Ahead

SUZHOU, China, and ROCKVILLE, MD., Mar. 21, 2022 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released its annual results for full year 2021, during which the company achieved significant progress realizing its vision of global innovation strategy including key Read More ›

First Patient Dosed in the Pivotal Phase II Study of Lisaftoclax

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has dosed the first patient in the pivotal Phase II study of the company’s novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Read More ›

Ascentage to Present Six Preclinical Studies at AACR 2022

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the results from six preclinical studies of the company’s five drug candidates: the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), two key products of the company’s apoptosis-targeted pipeline Read More ›